AIGH Capital Management’s Spruce Biosciences SPRB Stock Holding History

AIGH Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.1M	Hold	250,000	–	–	1.22%	24
2026 Q2	$13.5M	Buy	+250,000	New	+$14M	0.85%	21
2024 Q1	–	Sell	-28,318	Closed	-$6.22M	–	52
2023 Q4	$6.22M	Buy	28,318 +12,171	+75%	+$1.41M	2.46%	13
2023 Q3	$2.74M	Buy	16,147 +1,334	+9%	+$225K	1.3%	23
2023 Q2	$2.39M	Buy	14,813 +93	+0.6%	+$15.5K	0.97%	26
2023 Q1	$2.37M	Buy	+14,720	New	+$2.73M	0.87%	28

Other funds holding SPRB

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

Quinn Opportunity Partners Charlottesville, Virginia $1.85B AUM 1.27% 1-Year Est. Return

DMKJ

David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Persistent Asset Partners Hong Kong $362M AUM 191.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AIGH Capital Management's SPRB Position: Q3 2026 in Review

AIGH Capital Management held its Spruce Biosciences (SPRB) position steady in Q3 2026 at 250,000 shares worth $12.1M. The position accounts for 1.22% of the portfolio, ranked #24.

AIGH Capital Management first reported a position in SPRB in Q1 2023 and has held it in 6 quarters since. The position peaked at $13.5M in Q2 2026. 40 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.

AIGH Capital Management held 250,000 shares of Spruce Biosciences worth $12.1M as of Q3 2026.
AIGH Capital Management left its Spruce Biosciences share count unchanged in Q3 2026.
Spruce Biosciences made up 1.22% of AIGH Capital Management's portfolio in Q3 2026, its #24 holding.
AIGH Capital Management first reported a position in Spruce Biosciences in Q1 2023 and has held it in 6 quarters since.
AIGH Capital Management's Spruce Biosciences position peaked at $13.5M in Q2 2026.
40 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.

Based on AIGH Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.